Improving outcomes in pancreatic cancer: Key points in perioperative management

Table 3 Results of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma in terms of survival and mortality

	Mean Survival	Mortality	Estimated survival (%)
	(mo)	(%)	1-yr	2-yr
Gillen et al[2]	01:23.3	3.9	77.9	47.4
	02:20.5	7.1	79.8	50.1
Assifi et al[35]	01:15.1	N/P	N/P	N/P
	02:11.2
Andriulli et al[36]	01:18.8	N/P	91.7	86.3
	2:14		67.2	54.2

Referred only after surgical resection. 1: Group of patients with potentially resectable pancreatic adenocarcinoma; 2: Group of patients with borderline resectable pancreatic adenocarcinoma. N/P: Not provided.